|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||184.50 / 301.98|
The pharmaceutical company's new strategy emphasizes new product launches and international expansion.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
- First oral therapy to demonstrate efficacy and safety for uterine fibroids in two U.S. pivotal studies -
Doug Kass shares his thoughts on how he had one of his best days in recent memory, and warns you not to look in the rear view mirror.
Doug Kass shares his thoughts on animal spirits, and discusses his astonishment at some rising optimism.
In highlights from this week's trading diary and posts, Kass tells us about how he's selling some Allergan shares and how he feels about the jobless claims.
Trump's press conference puts a charge into an otherwise flat week. We add a position to the portfolio.
TheStreet's Jim Cramer weighs in on Donald Trump's comments regarding biotech and pharmaceuticals during his first press conference since the election.
Is the renewed Obamacare debate an opportunity to buy health care stocks?
But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
-- Company to Provide Full-Year 2017 Guidance --
Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.
He's never really been a stock market guy anyway.
Drug company Allergan is set to shift its focus towards accretive M&A and away from the early-stage pipeline acquisitions that have disappointed investors.
CEO Brent Saunders plans to reward shareholders after striking a slew of R&D acquisitions in the latter half of 2016.
America Online and Time Warner see the 17-year anniversary of their combination come and go, as both companies are involved in separate merger dramas today.
Allergan is out with two important deals on Monday, just as the J.P. Morgan Healthcare Conference begins.
The pharmaceutical maker announced two deals Monday as a part of the JP Morgan health care conference.
Doug Kass shares his thoughts on how January has a lot of nonsense, and reviews his investment troops.
Doug Kass shares his thoughts on the deepening of retail stocks' weakness and the Amazon Effect.
In highlights from this week's trading diary and posts, Kass tells us about how the market's optimism is misplaced and how to make a strategy from retail's wreckage.
Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.
Markets start 2017 on a high note, avoiding the pullbacks that have kicked off recent years.
Jim Cramer breaks down why it is so difficult to buy drug stocks right now.
We believe AGN's latest guidance, coupled with increased transparency and the potential for accretive tuck-in M&A, sparks a more-optimistic outlook for the future.
Having fallen short of earnings expectations in its third quarter, Allergan says non-GAAP earnings per share should see double-digit growth in the year ahead.